Cargando...
SUMO downregulates GLP-1-stimulated cAMP generation and insulin secretion
Glucagon-like peptide-1 (GLP-1)-based incretin therapy is becoming central to the treatment of type 2 diabetes. Activation of incretin hormone receptors results in rapid elevation of cAMP followed by enhanced insulin secretion. However, the incretin effect may be significantly impaired in diabetes....
Gardado en:
| Main Authors: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
American Physiological Society
2012
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3311292/ https://ncbi.nlm.nih.gov/pubmed/22234371 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1152/ajpendo.00486.2011 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|